Hoth Therapeutics

185 articles about Hoth Therapeutics

• Hoth Therapeutics Extends Partnership Agreement with REPROCELL

  10/19/2021

  Hoth Therapeutics, Inc. (NASDAQ: HOTH) has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in inflammatory bowel disease (IBD).

• Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis Patients

  10/12/2021

  Hoth Therapeutics, Inc. today announced that is has received Human Research Ethics Committee (HREC) clearance to commence cohort 2 of the Phase 1b clinical trial of BioLexa  Lotion for the treatment of mild to moderate atopic dermatitis in Australia. 

• Hoth Therapeutics Submits to Ethics Committee for Approval to Initiate Patient Cohort 2 in BioLexa Clinical Trial

  9/21/2021

  Hoth Therapeutics, Inc. announced today that a Safety Review Committee (SRC) has reviewed the safety data from the first cohort of healthy subjects and recommended that the study proceed to dosing patients with mild to moderate atopic dermatitis, also known as eczema. 

• Hoth Therapeutics Announces Positive Phase 1b Results for Completed First Cohort of Patient Trial of BioLexa

  9/8/2021

  Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced the completed safety results in Cohort 1 of its first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema.

• Hoth Therapeutics' mRNA 'Frameshifting' Therapy HT-KIT for Mast Cell Cancers Reduces Size, Spread - Research Published in Molecular Therapy

  8/11/2021

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today highlights recent findings from North Carolina State University, that its new treatment for mast cell cancers, known as HT-KIT, reduces the number of mast cells by "mutating" the messenger RNA (mRNA) before it can deliver instructions for manufacturing the gene responsible for cell proliferation.

• Hoth Therapeutics Initiates Preclinical Study of HT-ALZ for Alzheimer's Disease

  8/2/2021

  Hoth Therapeutics, Inc. announced today that it has initiated its preclinical study utilizing Hoth's HT-ALZ  in an animal model.

• Hoth Therapeutics Announces Positive Confirmatory Results from In Vivo Model of HT-003 Assets as Potential Treatment Against Acne

  7/13/2021

  Hoth Therapeutics, Inc. announced today that its HT-003 group of assets has yielded positive results in an in vivo acne therapeutic model.

• Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis

  6/28/2021

  Today, Hoth Therapeutics, Inc. , announced the safety results in Cohort 1 of its first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema.

• Hoth Therapeutics Announces Sponsored Research Agreement with Washington University for Novel Alzheimer's Therapeutic HT-ALZ

  6/7/2021

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), today announced that it has entered into a Sponsored Research Agreement with Washington University in St. Louis to support the continued research and development of HT-ALZ, a novel therapeutic for the treatment of symptoms related to Alzheimer's disease.

• Hoth Therapeutics Shares Positive Preclinical Results of Novel HT-KIT Therapeutic

  6/3/2021

  Shareholder Presentation Today to Further Highlight Results HT- KIT Reduces KIT expression and induces apoptosis of neoplastic human mast cells Inhibits tumor growth in humanized xenograft mast cell neoplasia models Reduces liver infiltration of neoplastic mast cells Reduces tumor growth in isograft models of mast cell neoplasia Reduces signs of mast cell leukemia in an isograft model of mutant mast cell neoplasia

• Hoth Therapeutics Plans Shareholder Presentation on HT-KIT Therapeutic's Preclinical Results for Rare Cancers

  6/1/2021

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today plans to host a virtual information session on its pipeline product, HT-KIT , a new molecular entity under development for treatment of mast cell-derived cancers and anaphylaxis, on Thursday, June 3rd for interested shareholders.

• Hoth Therapeutics Announces Participation at the American Society of Clinical Oncology (ASCO) Annual Meeting

  5/24/2021

  Hoth Therapeutics , Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will be an exhibitor at the American Society of Clinical Oncology (ASCO) Annual Meeting. Attendees will be able to visit the Hoth Therapeutics booth virtually starting May 24th through July 6, 2021 .

• Hoth Therapeutics Provides Shareholder Update on Novel Endocannabinoid Therapeutic for Cutaneous Lupus Erythematosus

  5/13/2021

   Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  announced today it plans to host a virtual information session on its pipeline product, HT-005 Z-Pods™ , a novel endocannibinoid treatment for patients with Cutaneous Lupus Erythematosus (CLE), on Tuesday, May 18th at 11:00am ET

• Hoth Therapeutics and Virginia Commonwealth University Expand Research Agreement for COVID-19 Therapeutic

  5/5/2021

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has expanded its sponsored research agreement with Virginia Commonwealth University (VCU) for a potential COVID-19 treatment.

• Hoth Therapeutics Announces Development of HT-KIT to Treat Multiple Orphan Diseases, Including Rare Cancers

  5/3/2021

  Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused clinical-stage biopharmaceutical company, announced it intends to pursue development of its HT-KIT mRNA Frame Shifting Therapeutic for multiple orphan diseases, which are rare diseases that affect less than 200,000 people in the US.

• Hoth Therapeutics' First in Human Clinical Trial for the Treatment of Atopic Dermatitis with BioLexa is Underway

  4/22/2021

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce the start of its First in Human clinical trial investigating topical BioLexa for the treatment of mild to moderate atopic dermatitis, also known as eczema.

• Hoth Therapeutics Announces its mRNA Frame Shifting Therapeutic Significantly Inhibits Tumor Growth in Mast Cell-Derived Cancers

  4/20/2021

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, announced that its novel anti-cancer therapeutic exhibited highly positive results in humanized mast cell neoplasm models, representative in vitro and in vivo models for aggressive, mast cell-derived cancers such as mast cell leukemia and mast cell sarcoma.

• Hoth Therapeutics Completes HT-001 Formulation Development for Upcoming Cancer Patient Clinical Trial

  4/12/2021

   Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, together with its manufacturing partner, has successfully completed the formulation for HT-001, a treatment for cancer patients suffering from cutaneous toxicities (skin, nails, scalp) due to EGFR inhibitor therapies

• Hoth Therapeutics Engages Worldwide Clinical Trials as Contract Research Organization for Phase 2a HT-001 Clinical Trial for Cancer Patients

  4/6/2021

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced that it has engaged Worldwide Clinical Trials ("Worldwide"), a full-service Contract Research Organization ("CRO") for its upcoming Phase 2a dose ranging clinical trial of HT-001 for treatment of cutaneous toxicities associated with EGFR inhibitor therapy for cancer patients.

• Hoth Therapeutics, Inc. Announces Notice of Allowance for a New Patent Application Related to A Method for Inhibiting Formation of a Biofilm

  4/5/2021

  Hoth Therapeutics, Inc. (Nasdaq: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced that the Brazilian Patent Office has issued a notice of allowance for a patent application related to the Company's method for inhibiting formation of biofilms.